Guido Tricot

High Impact

Professor

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

Internal Med, College of Medicine

97 h-index 716 pubs 36,331 cited

Research Areas

Links

ORCID Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Guido Tricot's research focuses on multiple myeloma, a hematologic malignancy. His work investigates the genetic underpinnings of the disease, including cytogenetic alterations that contribute to its complexity and progression. He also studies the tumor microenvironment, examining how multi-omics approaches can reveal alterations associated with multiple myeloma and its precursor stages.

Tricot's publications explore novel therapeutic strategies, such as bispecific chimeric antigen receptor (CAR)-T cells targeting both BCMA and CD24, and their potential to control or treat multiple myeloma growth. His research also addresses disparities in access to advanced therapies like CAR-T cells and bispecific antibodies for multiple myeloma, considering geographic and racial factors. He has published extensively on the clinical implications of minimal residual disease negativity and the role of specific genes, like TRIP13, in B cell malignancies and tumor progression, as well as the suppressive effects of CST6 on osteolytic bone disease in multiple myeloma.

With an h-index of 97 and over 716 publications, Tricot is recognized as a highly cited researcher. He collaborates with several colleagues at the University of Arkansas for Medical Sciences, including John D. Shaughnessy, Clyde Bailey, Sharmilan Thanendrarajan, and Maurizio Zangari.

Metrics

h-index: 97
Publications: 716
Citations: 36,331

Selected Publications

Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

2 citations DOI OpenAlex
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

1 citation DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

5 citations DOI OpenAlex
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)

DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

1 citation DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

22 citations DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)

8 citations DOI OpenAlex
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024)

2 citations DOI OpenAlex
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)

4 citations DOI OpenAlex
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)

7 citations DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

33 citations DOI OpenAlex
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)

8 citations DOI OpenAlex
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)

17 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

Gene expression profiling vs MRD assessment in Myeloma NIH Principal Investigator
UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator
UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator
UARK 2003-01, Stem Cell Mobilization and Transplantation of Proven and/or Predicted Poor Mobilizers with Mutliple Myeloma AnorMED, Inc. Principal Investigator